November 2026 Newsletter

Rethinking Prostate Cancer Care: Early Detection, Precision Diagnosis and New Treatments

Prostate cancer care is undergoing a significant shift. For many years, the central challenge was detecting the disease early enough to improve survival without exposing men to unnecessary biopsies and treatment. Today, advances in screening recommendations, diagnostic imaging and targeted therapies are changing how clinicians approach that balance. The focus is increasingly on identifying men at greatest risk, distinguishing clinically significant cancers from those unlikely to cause harm, and selecting treatments that reflect the characteristics of each patient's disease.

The need for this shift is considerable. In 2022, approximately 1.5 million men were diagnosed with prostate cancer worldwide, with around 400,000 deaths recorded. The global burden is expected to rise substantially over the coming decades, with low- and middle-income countries projected to experience a particularly significant increase. At the same time, age, family history and ancestry influence individual risk, while differences in access to screening and specialist care shape outcomes. The challenge is therefore not simply to detect more prostate cancer, but to identify clinically significant disease earlier, make more accurate treatment decisions and ensure that advances in care reach the populations that need them most.

Want to read on? Join our network and receive access to our member-only newsletter.

As a member of Global Health Impact Network, you'll enjoy full access to the newsletter, featuring exclusive industry insights, network updates, and opportunities to consult, advise, and invest. Don’t miss out — join today and unlock your benefits.

Next
Next

October 2026 Newsletter